Program
mavorixafor
Also written as “Mavorixafor”, “X4P-001” and “AMD11070”.
Its studies are mostly in Neutropenia · Carcinoma, Renal Cell · Hepatic Insufficiency · Waldenstrom Macroglobulinemia · Triple Negative Breast Neoplasms, led by 3 companies.
Drug pageMavorixafor: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| X4 Pharmaceuticalsits history only | 122 open or running | phase 3since Jun 19, 2019 | Jan 20, 2016 | Sep 2027phase 3 · NCT06056297 |
| Abbisko Cayman | 10 open or running | phase 2since Sep 25, 2021 | Sep 25, 2021 | none ahead |
| Sanofiits history only | 10 open or running | phase 1since Aug 3, 2006 | Aug 3, 2006 | none ahead |
Also a collaborator on its studies: Covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Abbisko Cayman only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2017Named mavorixaforINNProposed as its International Nonproprietary Name in WHO's List 118 · before, X4P-001, AMD11070
- Sep 25, 2021First study: phase 2 study in Triple Negative Breast NeoplasmsFirst studyNCT05103917 · 24 enrolled · China
TargetBeta
“An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), ”NCIt, by rule
“C-X-C chemokine receptor type 4 antagonist”ChEMBL 37, by rule
Studies
The one study Abbisko Cayman leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05103917Triple Negative Breast Neoplasms · China | 2 | UNKNOWN | Nov 24, 2022 | 24 |
How it is read
Names in the registry
- “Mavorixafor”, 7 entries
- “X4P-001”, 6 entries
- “AMD11070”, 1 entry
Conditions, from the studies’ own filings
- Neutropenia, 3 studies
- Carcinoma, Renal Cell, 2 studies
- Hepatic Insufficiency, 1 study
- Waldenstrom Macroglobulinemia, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.